

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

211192Orig1s000

Trade Name: Tibsovo® tablets; 250 mg

Generic or Proper Name: ivosidenib

Sponsor: Agios Pharmaceuticals, Inc.

Approval Date: July 20, 2018

Indication: For the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

CENTER FOR DRUG EVALUATION AND RESEARCH

211192Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Officer/Employee List	X
Multidiscipline Review(s) <ul style="list-style-type: none">• Summary Review• Office Director• Cross Discipline Team Leader• Clinical• Non-Clinical• Statistical• Clinical Pharmacology	X
Product Quality Review(s)	X
Clinical Microbiology / Virology Review(s)	
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	X
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21192Orig1s000

APPROVAL LETTER



NDA 211192

NDA APPROVAL

Agios Pharmaceuticals, Inc.
Attention: Jamie Cohen, PhD
Director, Regulatory Affairs
88 Sidney Street
Cambridge, MA 02139

Dear Dr. Cohen:

Please refer to your New Drug Application (NDA) dated December 21, 2017, received December 21, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tibsovo[®] (ivosidenib) tablets; 250 mg.

This new drug application provides for the use of Tibsovo[®] (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the carton and immediate container labels submitted on May 16, 2018, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to

the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 211192.**” Approval of this submission by FDA is not required before the labeling is used.

ADVISORY COMMITTEE

Your application for ivosidenib was not referred to an FDA advisory committee because the application did not raise significant safety or efficacy issues.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify an unexpected serious risk of long-term toxicities of ivosidenib or assess a signal of excessive drug toxicity from impaired hepatic function on the pharmacokinetics of ivosidenib.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA will not be sufficient to assess these serious risks.

Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess these risks.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following trials:

PMR 3444-1 Characterize the long-term safety of ivosidenib in patients with relapsed or refractory acute myeloid leukemia (AML). Submit the final study report and data set with 3 years of follow-up from ongoing Study AG120-C-001, *A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety,*

Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation. Include data from approximately 205 patients with relapsed or refractory AML.

Include in the final study report the exploratory subgroup analyses and corresponding subject level data related to pre- and post-treatment cytogenetics, specific IDH1 mutations, and mutation analyses for other genes as obtained under the trial protocol.

The timetable you submitted on July 13, 2018 states that you will conduct this trial according to the following schedule:

Trial Completion: 5/2021
Final Report Submission: 3/2022

- PMR 3444-2 Complete your ongoing Study AG120-C-012, *A Phase 1, open-label, single-dose study to evaluate the pharmacokinetics, safety, and tolerability of AG-120 in subjects with mild or moderate hepatic impairment or normal hepatic function.*

The timetable you submitted on July 13, 2018 states that you will conduct this study according to the following schedule:

Final Report Submission: 10/2018

- PMR 3444-3 Conduct a clinical pharmacokinetic trial to determine an appropriate safe dose of ivosidenib in patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test with hepatic impairment (moderate) dosed with ivosidenib to steady-state vs. patients with normal hepatic function dosed with ivosidenib to steady-state. This may be performed as a sub-study in the ongoing Phase 1 Study AG120-C-001, *A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation.* This trial should be designed and conducted in accordance with the FDA Guidance for Industry entitled *Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling.* Depending on the results, a clinical pharmacokinetic trial in patients with severe hepatic impairment may be required.

The timetable you submitted on July 13, 2018 states that you will conduct this study according to the following schedule:

Final Protocol Submission: 4/2019
Trial Completion: 11/2022
Final Report Submission: 6/2023

Submit clinical protocol(s) to your IND 119341 with a cross-reference letter to this NDA. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate: **Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).**

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the prescribing information, Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the prescribing information, at the time of initial dissemination or publication, accompanied by a

Form FDA 2253. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at <http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>.

POST APPROVAL FEEDBACK MEETING

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call Laura Wall, Regulatory Project Manager, at (301) 796-2237.

Sincerely,

{See appended electronic signature page}

Richard Pazdur, MD
Office Director
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

Enclosure:
Content of Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

RICHARD PAZDUR
07/20/2018